Company intelligence / Profile preview

Innoblative Designs

Ownership: Private
Employees: ~49
Development stage: Commercial

Overview

The company's lead product has received U.S. Investigational Device Exemption (IDE) approval and has been used successfully in first-in-human procedures to treat breast cancer. The device aims to improve outcomes by ablating residual cancer cells at the surgical margin following lumpectomy. No large-scale pivotal trial or commercial launch data available as of June 2025.

Therapeutic areas: OncologyRheumatology
Modalities: DeviceElectrosurgical deviceRadiofrequency ablation system
Industry: Therapeutic Medical Devices

Partnerships

Northwestern University/Feinberg School of Medicine collaboration via inventor David Mahvi

Beyond the preview

Go deeper on Innoblative Designs.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Innoblative Designs.

Explore the full profile